Erratum: Examining bias in studies of statin treatment and survival in patients with cancer (JAMA Oncology (2017) DOI: 10.1001/jamaoncol.2017.2752);Examining bias in studies of statin treatment and survival in patients with cancer

JAMA Oncology

Volumn 4, Issue 1, 2018, Pages 63-70

  Emilsson, Louise ^a,b,c   García Albéniz, Xabier ^a   Logan, Roger W ^a   Caniglia, Ellen C ^a   Kalager, Mette ^a,b   Hernán, Miguel A ^a,d  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF OSLO   (Norway)

^c Primary Care Research Unit   (Sweden)

^d HARVARD MIT DIVISION OF HEALTH SCIENCES AND TECHNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PITAVASTATIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

AGED; ARTICLE; BLADDER CANCER; BREAST CANCER; CANCER INCIDENCE; CANCER MORTALITY; CANCER SPECIFIC SURVIVAL; CANCER STAGING; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; CHRONIC OBSTRUCTIVE LUNG DISEASE; COLORECTAL CANCER; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG USE; FEMALE; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MORTALITY RISK; OBSERVATIONAL STUDY; OVERALL SURVIVAL; PNEUMONIA; PREVALENCE; PROSTATE CANCER; SELECTION BIAS; TIME TO TREATMENT; VERY ELDERLY; CANCER REGISTRY; COMORBIDITY; COMPLICATION; INCIDENCE; NEOPLASM; PUBLICATION; PUBLISHING; REGISTER; STATISTICAL BIAS; STATISTICS AND NUMERICAL DATA; SURVIVAL ANALYSIS; UNITED STATES;

BIAS; CAUSE OF DEATH; COMORBIDITY; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INCIDENCE; MALE; NEOPLASMS; PUBLICATION BIAS; PUBLICATIONS; REGISTRIES; SEER PROGRAM; SURVIVAL ANALYSIS; UNITED STATES;

EID: 85041022552     PISSN: 23742437     EISSN: 23742445     Source Type: Journal    
DOI: 10.1001/jamaoncol.2017.2813     Document Type: Erratum

References (39)

1. Meng Y, Liao YB, Xu P, WeiWR, Wang J. Statin use and mortality of patients with prostate cancer: Ameta-analysis. Onco Targets Ther. 2016;9: 1689-1696.
2. Manthravadi S, Shrestha A, Madhusudhana S. Impact of statin use on cancer recurrence and mortality in breast cancer: A systematic review and meta-analysis. Int J Cancer. 2016;139(6):1281-1288.
3. Gray RT, Coleman HG, Hughes C, Murray LJ, Cardwell CR. Statin use and survival in colorectal cancer: Results from a population-based cohort study and an updated systematic review and meta-analysis. Cancer Epidemiol. 2016;45:71-81.
4. Chou R, Dana T, Blazina I, DaegesM, Jeanne TL. Statins for prevention of cardiovascular disease in adults: Evidence report and systematic review for the US Preventive Services Task Force. JAMA. 2016; 316(19):2008-2024.
5. Caporaso NE. Statins and cancer-related mortality-let's work together. N Engl J Med. 2012; 367(19):1848-1850.
6. Spampanato C, De Maria S, Sarnataro M, et al. Simvastatin inhibits cancer cell growth by inducing apoptosis correlated to activation of Bax and down-regulation of BCL-2 gene expression. Int J Oncol. 2012;40(4):935-941.
7. Lévesque LE, Hanley JA, Kezouh A, Suissa S. Problem of immortal time bias in cohort studies: Example using statins for preventing progression of diabetes. BMJ. 2010;340:b5087.
8. Danaei G, Tavakkoli M, Hernán MA. Bias in observational studies of prevalent users: Lessons for comparative effectiveness research from a meta-analysis of statins. Am J Epidemiol. 2012;175 (4):250-262.
9. Warren JL, Klabunde CN, Schrag D, Bach PB, Riley GF. Overview of the SEER-Medicare data: Content, research applications, and generalizability to the United States elderly population. Med Care. 2002;40(8)(suppl):IV-3-IV-18.
10. Black L, Runken MC, Eaddy M, Shah M. Chronic disease prevalence and burden in elderly men: An analysis of Medicare medical claims data. J Health Care Finance. 2007;33(4):68-78.
11. Herzog CA, Muster HA, Li S, Collins AJ. Impact of congestive heart failure, chronic kidney disease, and anemia on survival in the Medicare population. J Card Fail. 2004;10(6):467-472.
12. Sandgren PE, Murray AM, Herzog CA, et al. Anemia and new-onset congestive heart failure in the general Medicare population. J Card Fail. 2005; 11(2):99-105.
13. Spettell CM, Wall TC, Allison J, et al. Identifying physician-recognized depression from administrative data: Consequences for quality measurement. Health Serv Res. 2003;38(4): 1081-1102.
14. CCW Task Order 10 Inter-Agency Panel working document and input from subject matter experts. https://ccwdata.org/cs/groups/public/documents /document/clin-cond-refer.pdf. Accessed August 15, 2016.
15. Hedley Dodd A, Gleason P. Using the MAX-NHANES Merged Data to Evaluate the Association of Obesity and Medicaid Costs [2013]. https://www.cms.gov/Research-Statistics-Dataand-Systems/Computer-Data-and-Systems /MedicaidDataSourcesGenInfo/Downloads/MAX -IB16-MAX-NHANES.PDF. Accessed August 15, 2016.
16. Klabunde CN, Potosky AL, Legler JM, Warren JL. Development of a comorbidity index using physician claims data. J Clin Epidemiol. 2000;53 (12):1258-1267.
17. Hernán MA, Sauer BC, Hernández-Díaz S, Platt R, Shrier I. Specifying a target trial prevents immortal time bias and other self-inflicted injuries in observational analyses. J Clin Epidemiol. 2016;79: 70-75.
18. ThompsonWA Jr. On the treatment of grouped observations in life studies. Biometrics. 1977;33(3): 463-470.
19. Hernan M, Robins J. Causal Inference. Boca Raton, FL: Chapman & Hall/CRC; 2017.
20. Luo Y, She DL, Xiong H, Fu SJ, Yang L. The prognostic effect of statin use on urologic cancers: An updated meta-analysis of 35 observational studies. Medicine (Baltimore). 2015; 94(36):e1523.
21. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177-188.
22. Murtola TJ, Visvanathan K, Artama M, Vainio H, Pukkala E. Statin use and breast cancer survival: A nationwide cohort study from Finland. PLoS One. 2014;9(10):e110231.
23. Katz MS, Carroll PR, Cowan JE, Chan JM, D'Amico AV. Association of statin and nonsteroidal anti-inflammatory drug use with prostate cancer outcomes: Results from CaPSURE. BJU Int. 2010; 106(5):627-632.
24. Lakha F, Theodoratou E, Farrington SM, et al. Statin use and association with colorectal cancer survival and risk: Case control study with prescription data linkage. BMC Cancer. 2012;12:487.
25. Geybels MS, Wright JL, Holt SK, Kolb S, Feng Z, Stanford JL. Statin use in relation to prostate cancer outcomes in a population-based patient cohort study. Prostate. 2013;73(11):1214-1222.
26. Desai P, Lehman A, Chlebowski RT, et al. Statins and breast cancer stage and mortality in the Women's Health Initiative. Cancer Causes Control. 2015;26(4):529-539.
27. Brewer TM, Masuda H, Liu DD, et al. Statin use in primary inflammatory breast cancer: A cohort study. Br J Cancer. 2013;109(2):318-324.
28. Caon J, PaquetteM, Hamm J, Pickles T. Does statin or ASA affect survival when prostate cancer is treated with external beam radiation therapy?. Prostate Cancer. 2014;2014(4):184297.
29. Nielsen SF, Nordestgaard BG, Bojesen SE. Statin use and reduced cancer-related mortality. N Engl J Med. 2012;367(19):1792-1802.
30. Siddiqui AA, Nazario H, Mahgoub A, Patel M, Cipher D, Spechler SJ. For patients with colorectal cancer, the long-term use of statins is associated with better clinical outcomes. Dig Dis Sci. 2009;54 (6):1307-1311.
31. Shao YY, Hsu CH, Yeh KH, et al. Statin use is associated with improved prognosis of colorectal cancer in Taiwan. Clin Colorectal Cancer. 2015;14(3): 177-184.e4.
32. da Silva RD, Xylinas E, Kluth L, et al. Impact of statin use on oncologic outcomes in patients with urothelial carcinoma of the bladder treated with radical cystectomy. J Urol. 2013;190(2):487-492.
33. Hoffmeister M, Jansen L, Rudolph A, et al. Statin use and survival after colorectal cancer: The importance of comprehensive confounder adjustment. J Natl Cancer Inst. 2015;107(6):djv045.
34. Chan JM, Kenfield SA, Paciorek A, Platz EA, Giovannucci EL, Stampfer MJ. Postdiagnostic statin use and the risk of lethal prostate cancer in the health professionals follow-up study. Cancer Epidemiol Biomarkers Prev. 2015;24(10):1638-1640.
35. Suissa S, Dell'aniello S, Vahey S, Renoux C. Time-window bias in case-control studies: Statins and lung cancer. Epidemiology. 2011;22(2):228-231.
36. Hernández-Díaz S. Name of the bias and sex of the angels. Epidemiology. 2011;22(2):232-233.
37. Hernán MA, Robins JM. Using big data to emulate a target trial when a randomized trial is not available. Am J Epidemiol. 2016;183(8):758-764.
38. Dale KM, Coleman CI, Henyan NN, Kluger J, White CM. Statins and cancer risk: Ameta-analysis. JAMA. 2006;295(1):74-80.
39. Emberson JR, Kearney PM, Blackwell L, et al; Cholesterol Treatment Trialists' (CTT) Collaboration. Lack of effect of lowering LDL cholesterol on cancer: Meta-analysis of individual data from 175, 000 people in 27 randomised trials of statin therapy. PLoS One. 2012;7(1):e29849.